Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezra Y Rosen

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
NPJ Precision Oncology|July 28, 2024
Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancerNicholas Mai, Jie-Fu Chen, Satshil Rana, et al.
Neuron|September 29, 2011
Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signalingEzra Y Rosen, Eric M Wexler, Revital Versano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2020
A Performance Comparison of Commonly Used Assays to Detect RET FusionsSoo-Ryum Yang, Umut Aypar, Ezra Y Rosen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 4, 2019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfallsJames P Solomon, Irina Linkov, Andrea Rosado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
Nature Communications|November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologiesYonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumorsIan M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
JCO Precision Oncology|September 11, 2020
Real-World Outcomes of an Automated Physician Support System for Genome-Driven OncologyJessica J Tao, Michael H Eubank, Alison M Schram, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerJacob A Boyer, Ezra Y Rosen, Malvika Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
NPJ Precision Oncology|July 28, 2024
Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancerNicholas Mai, Jie-Fu Chen, Satshil Rana, et al.
Neuron|September 29, 2011
Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signalingEzra Y Rosen, Eric M Wexler, Revital Versano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2020
A Performance Comparison of Commonly Used Assays to Detect RET FusionsSoo-Ryum Yang, Umut Aypar, Ezra Y Rosen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 4, 2019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfallsJames P Solomon, Irina Linkov, Andrea Rosado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
Nature Communications|November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologiesYonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumorsIan M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
JCO Precision Oncology|September 11, 2020
Real-World Outcomes of an Automated Physician Support System for Genome-Driven OncologyJessica J Tao, Michael H Eubank, Alison M Schram, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerJacob A Boyer, Ezra Y Rosen, Malvika Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Pageof 2